首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Potential Molecular Mechanisms of Chaihu-Shugan-San in Treatment of Breast Cancer Based on Network Pharmacology
【24h】

Potential Molecular Mechanisms of Chaihu-Shugan-San in Treatment of Breast Cancer Based on Network Pharmacology

机译:基于网络药理学治疗乳腺癌的柴胡舒甘 - 舒甘 - 急性分子机制

获取原文
           

摘要

Breast cancer is one of the most common cancers endangering women’s health all over the world. Traditional Chinese medicine is increasingly recognized as a possible complementary and alternative therapy for breast cancer. Chaihu-Shugan-San is a traditional Chinese medicine prescription, which is extensively used in clinical practice. Its therapeutic effect on breast cancer has attracted extensive attention, but its mechanism of action is still unclear. In this study, we explored the molecular mechanism of Chaihu-Shugan-San in the treatment of breast cancer by network pharmacology. The results showed that 157 active ingredients and 8074 potential drug targets were obtained in the TCMSP database according to the screening conditions. 2384 disease targets were collected in the TTD, OMIM, DrugBank, GeneCards disease database. We applied the Bisogenet plug-in in Cytoscape 3.7.1 to obtain 451 core targets. The biological process of gene ontology (GO) involves the mRNA catabolic process, RNA catabolic process, telomere organization, nucleobase-containing compound catabolic process, heterocycle catabolic process, and so on. In cellular component, cytosolic part, focal adhesion, cell-substrate adherens junction, and cell-substrate junction are highly correlated with breast cancer. In the molecular function category, most proteins were addressed to ubiquitin-like protein ligase binding, protein domain specific binding, and Nop56p-associated pre-rRNA complex. Besides, the results of the KEGG pathway analysis showed that the pathways mainly involved in apoptosis, cell cycle, transcriptional dysregulation, endocrine resistance, and viral infection. In conclusion, the treatment of breast cancer by Chaihu-Shugan-San is the result of multicomponent, multitarget, and multipathway interaction. This study provides a certain theoretical basis for the treatment of breast cancer by Chaihu-Shugan-San and has certain reference value for the development and application of new drugs.
机译:乳腺癌是危及世界各地女性健康的最常见的癌症之一。中药越来越被认为是乳腺癌可能的互补和替代治疗。柴胡曙光 - 山是一种中医处方,广泛用于临床实践。它对乳腺癌的治疗效果引起了广泛的关注,但其行动机制仍然尚不清楚。在这项研究中,我们通过网络药理学探讨了柴胡曙光-SAN治疗乳腺癌的分子机制。结果表明,根据筛选条件,在TCMSP数据库中获得了157种活性成分和8074个潜在药物靶标。在TTD,OMIM,药物银行,Genecards疾病数据库中收集了2384个疾病靶标。我们在Cytoscape 3.7.1中应用了Bisogenet插件,获得了451个核心目标。基因本体学(GO)的生物过程涉及mRNA分解代谢过程,RNA分解酵母过程,端粒组织,含核碱基化合物分解代谢过程,杂环分解法,等等。在细胞组分中,细胞骨部分,局部粘附,细胞基质粘附结和细胞基板结与乳腺癌高度相关。在分子函数类别中,大多数蛋白质被寻址到泛素样蛋白连接酶结合,蛋白质结构域特异性结合和NOP56P相关的预rRNA复合物。此外,Kegg途径分析结果表明,该途径主要涉及细胞凋亡,细胞周期,转录缺点,内分泌抵抗和病毒感染。总之,柴胡曙光-SAN的乳腺癌的治疗是多组分,多元化和多路径相互作用的结果。本研究为柴胡曙光-SAN治疗乳腺癌的一种理论依据,并对新药的开发和应用具有一定的参考价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号